[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344427-105":59,"doc-detail-344427-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","osteopontin-in-pancreatic-cancer-a-systematic-review","Osteopontin in pancreatic cancer - A systematic review","","The present study systematically analyzed published literature on osteopontin in pancreatic cancers. PubMed yielded 105 relevant references before the cut-off date, plus 39 studies describing osteopontin in non-cancerous pancreatic conditions. Osteopontin supports pancreatic development and function and is upregulated in pancreatic malignancies, functioning as a blood biomarker for transformation, progression, and survival prospects. Splice variants OPN-b and OPN-c improve cancer-specific diagnosis, while models link osteopontin to metastasis, tropism, stemness, angiogenesis, and chemoresistance. OPN-a regulates pancreatic tumor immunology, especially macrophage activity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/osteopontin-in-pancreatic-cancer-a-systematic-review/344427/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/osteopontin-in-pancreatic-cancer-a-systematic-review/344427.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the scope of the systematic review on osteopontin and pancreatic cancer?","Question",{"text":112,"@type":113},"The review analyzed PubMed-indexed studies using defined search terms. It included 105 pertinent references and also considered 39 results from osteopontin studies in non-cancerous pancreatic conditions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does osteopontin relate to pancreatic cancer progression and prognosis?",{"text":117,"@type":113},"Osteopontin is reported as upregulated in pancreatic cancers and may serve as a blood biomarker reflecting transformation, progression, and survival prospects.",{"name":119,"@type":110,"acceptedAnswer":120},"Which osteopontin splice variants are highlighted for diagnosis, and what roles are described from models?",{"text":121,"@type":113},"The splice variants OPN-b and OPN-c are emphasized for upgraded cancer-specific diagnosis. Animal and cellular models are described as clarifying osteopontin’s roles in metastasis, tropism, stemness, angiogenesis, and chemoresistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344427,1790407161,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","MEDICINE INTERNATIONAL 6: 26, 2026  \nOsteopontin in pancreatic cancer: A systematic review  \nGEORG F. WEBER  \nJames L. Winkle College of Pharmacy and Cancer Center, University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA  \nReceived July 30, 2025; Accepted February 17, 2026  \nDOI: 10. 3892/mi.2026.310  \nAbstract. The present study analyzed the available literature on osteopontin in pancreatic cancers. Before the cut‑off date, PubMed listed 105 pertinent references, plus 39 results covering osteopontin in non‑cancerous conditions of the pancreas. The molecule fulfills physiologic roles in pancreatic development and function, including islet survival and protection from hyperglycemia . Osteopontin has been found upregulated in cancers of the pancreas and may serve as a biomarker for transformation, progression or survival prospects, particularly in conjunction with other molecular indicators. It has been reli‑ ably corroborated as a blood biomarker for these malignancies. In particular, the measurement of the cancer‑specific osteo‑ pontin splice variants OPN‑b and OPN‑c achieves upgraded diagnosis. Animal and cellular models have elucidated the functions of osteopontin in support of the metastasis, tropism and stemness of the cancer cells, as well as roles in angiogenesis and chemoresistance. As the full‑length form of osteopontin, OPN‑a, serves as an inducer cytokine for cellular immunity, it has been characterized by several studies as a regulator in pancreatic tumor immunology, particularly in macrophages. Osteopontin induction and biologic effects are associated with various premalignant and predisposing conditions, including intraductal papillary mucinous neoplasms, smoking, pancre‑ atitis and kidney disease. In diabetes and obesity, the molecule plays complex roles that may either attenuate or promote disease progression. While osteopontin has emerged as a key physiological regulator of pancreatic functions, its aberrant expression and splicing in cancers of the pancreas supports tumor progression and may serve early detection as well as prognostication. The splice variants have potential to become therapeutic targets in anti‑metastasis regimens.  \nCorrespondence to: Dr Georg F. Weber, James L. Winkle College of Pharmacy and Cancer Center, University of Cincinnati Cancer Center, 231 Albert Sabin Way, OH 45267, USA  \nE‑mail: [georg.weber@uc.edu](georg.weber@uc.edu)  \nKey words: pancreatic cancer, osteopontin, tumor progression, biomarker, tumor immunology, premalignant lesion, smoking, pancreatitis, diabetes  \nIntroduction  \nCancer of the pancreas is often detected at a late stage. At that juncture, it has commonly disseminated and is therefore afflicted by a poor prognosis. A better understanding of the molecular mechanisms underlying the disease, in particular its progression and dissemination, should point the way to improved clinical care. In tumor stage progression and metas‑ tasis formation of this malignancy, osteopontin (also known as OPN or SPP1) has been known to be a major contributor (1‑3) . Hence, it is of importance to elucidate the knowledge base about this secreted phosphoglycoprotein, pertaining to the induction of its aberrant expression and its splice variants (4,5) in pancreatic cancers. Such insights may improve early detec‑ tion/diagnosis and can point the way toward novel therapeutic targets associated with tumor spread. For this purpose, the present systematic review was conducted, analyzing studies found on PubMed‑listed database on this subject (Fig. S1) .  \nData and methods  \nSource literature . Publications in the PubMed database with the key phrase ‘pancreas cancer OR pancreatic cancer AND osteopontin’ yielded 105 references (cut‑off date, December 31, 2025) . A total of 26 articles were found not to be pertinent, predominantly as they studied cancers of different organ origin (mostly liver cancers, but also colorectal and gastric cancers); 1 article had been retracted. Of note,‘osteopo","cbCaikSYlzdPqjYh","https://ap.wps.com/l/cbCaikSYlzdPqjYh","pdf",2852056,"English","# Introduction\n# Data and methods\n## Source literature\n## Analysis\n## Data extraction\n# Results\n## History and molecular characteristics of osteopontin","[{\"question\":\"What was the scope of the systematic review on osteopontin and pancreatic cancer?\",\"answer\":\"The review analyzed PubMed-indexed studies using defined search terms. It included 105 pertinent references and also considered 39 results from osteopontin studies in non-cancerous pancreatic conditions.\"},{\"question\":\"How does osteopontin relate to pancreatic cancer progression and prognosis?\",\"answer\":\"Osteopontin is reported as upregulated in pancreatic cancers and may serve as a blood biomarker reflecting transformation, progression, and survival prospects.\"},{\"question\":\"Which osteopontin splice variants are highlighted for diagnosis, and what roles are described from models?\",\"answer\":\"The splice variants OPN-b and OPN-c are emphasized for upgraded cancer-specific diagnosis. Animal and cellular models are described as clarifying osteopontin’s roles in metastasis, tropism, stemness, angiogenesis, and chemoresistance.\"}]","Osteopontin in pancreatic cancer - A systematic review | PDF",1790053728,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62d6303e1e6b12d8adec4ffd99d60d13.webp",983,1357,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a851ea2ee20e1b50b4a8fe9dd94ba099.webp",982,1356,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f90ea55c669765fca83af9147ff4e59.webp",981,1354,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5639c3329e46f0a9c9eb290b9a692aa2.webp",980,1353]